Katharina Kichko supports the first Personalized Medicine learnings as she provides an approach overview in general as well as reimbursement and regulatory policies in particular. In focus stays analysis of the current Personalized Medicine in the U.S. and Germany as well as its preconditions for a wider implementation in the medical practice. Results have shown that the U.S. – as early knower – have the most projects as well as personalized drugs and therapies, while Germany – as a follower – has a significant number of projects and personalized products and more to come in future.

Katharina Kichko supports the first Personalized Medicine learnings as she provides an approach overview in general as well as reimbursement and regulatory policies in particular. In focus stays analysis of the current Personalized Medicine in the U.S. and Germany as well as its preconditions for a wider implementation in the medical practice. Results have shown that the U.S. – as early knower – have the most projects as well as personalized drugs and therapies, while Germany – as a follower – has a significant number of projects and personalized products and more to come in future.

Katharina Kichko supports the first Personalized Medicine learnings as she provides an approach overview in general as well as reimbursement and regulatory policies in particular. In focus stays analysis of the current Personalized Medicine in the U.S. and Germany as well as its preconditions for a wider implementation in the medical practice. Results have shown that the U.S. – as early knower – have the most projects as well as personalized drugs and therapies, while Germany – as a follower – has a significant number of projects and personalized products and more to come in future.